Strata Skin Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$SSKN
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 10, 2025
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company. ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 5.07 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
On December 10, 2025 the Company held its annual meeting of stockholders (the “Annual Meeting”). The matters voted upon were:
(1) the election of five director nominees to the Company’s board of directors to serve until the next annual meeting of the Company’s stockholders or until their
successors are elected and qualify, subject to their prior death, resignation or removal;
(2) to approve an amendment to our Amended and Restated 2016 Omnibus Incentive Plan (the “2016 Omnibus Incentive Plan”) to increase the number of shares of
common stock reserved for issuance thereunder by 520,000 shares;
(3) to ratify the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2025.
The results of the voting were as follows:
(1) Each of the director nominees to the Company’s board of directors was elected:
|
Nominees
|
Votes For
|
Votes Withheld
|
Broker Non-Vote
|
|
Dr. Uri Geiger
|
2,208,832
|
46,203
|
1,010,399
|
|
Dr. Irit Yaniv
|
2,180,045
|
74,990
|
1,010,399
|
|
Christina Allgeier
|
2,180,415
|
74,620
|
1,010,399
|
|
Shmuel Rubinstein
|
2,225,313
|
29,718
|
1,010,399
|
|
Dr. Dolev Rafaeli
|
2,193,145
|
61,890
|
1,010,399
|
(2) to approve an amendment to the Company’s Amended and Restated 2016 Omnibus Incentive Plan to increase the number of shares of common stock reserved for
issuance thereunder by 520,000 shares
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Vote
|
|
2,158,427
|
93,484
|
3,124
|
1,010,399
|
(3) to ratify the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. as our independent registered public accounting firm for the
fiscal year ending December 31, 2025, was approved
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Vote
|
|
|
3,181,648
|
62,698
|
21,088
|
0
|
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: December 10, 2025
|
By:
|
/s/ John Gillings
|
|
|
John Gillings
|
|||
|
Chief Accounting Officer
|
|||
-3-